跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

ZAMBON SPA

首页临床试验发起方与机构ZAMBON SPA

ZAMBON SPA

ACTIVE

VIA LILLO DEL DUCA 10, Bresso, Milano, 意大利www.zambon.comSubsidiary

隶属于 ZAMBON COMPANY SPA

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

相关临床试验

44

20 进行中

药物批准

4

批准总数

监管机构

2

监管机构数

成立时间

N/A

概览

试验阶段分布

阶段

试验数

占比

1 期

26

59.1%

3 期

10

22.7%

2 期

3

6.8%

不适用

1

2.3%

4 期

1

2.3%

试验状态分布

进行中（未招募）

20

45.5%

已完成

20

45.5%

招募中

1

2.3%

终止

2

4.5%

撤回

1

2.3%

相关临床试验

该机构主办的试验（44）

A Retrospective Chart Review Study of Patients With CLAD-BOS Post Lung Transplantation

Jun 2024284 名受试者

Clinical research study to investigate efficacy and safety of Liposomal Cyclosporine A (L-CsA) in patients with Bronchiolitis Obliterans Syndrome after Single or Double Lung Transplantation.

Dec 2022220 名受试者

Clinical research study to investigate efficacy and safety of Liposomal Cyclosporine A (L-CsA) in patients with Bronchiolitis Obliterans Syndrome after Single or Double Lung Transplantation.

进行中（未招募）

Nov 2021220 名受试者

Clinical research study to investigate efficacy and safety of Liposomal Cyclosporine A (L-CsA) in patients with Bronchiolitis obliterans syndrome after double lung transplantation.

进行中（未招募）

Sep 2021170 名受试者

A Single and Multiple Dose Study to Assess How the Drug Enters, Moves Through and Exits the Body, Safety and Tolerability of Safinamide in Healthy Adult Chinese Volunteers

Jun 202124 名受试者

A double-blind, placebo-controlled, multi-centre, clinical trial to investigate the efficacy and safety of 12 months of therapy with inhaled colistimethate sodium in the treatment of subjects with non-cystic fibrosis bronchiectasis chronically infected with Pseudomonas aeruginosa (P. aeruginosa)

进行中（未招募）

Jan 2021420 名受试者

A study evaluating the safety and efficacy of safinamide for patients with Multiple System Atrophy

进行中（未招募）

Jan 202148 名受试者

A double-blind, placebo controlled, multicentre, clinical trial to investigate the efficacy and safety of 12 months of therapy with inhaled colistimethate sodium in the treatment of subjects with non-cystic fibrosis bronchiectasischronically infected with Pseudomonas aeruginosa (P. aeruginosa)

进行中（未招募）

Oct 2020420 名受试者

第 1 页，共 6 页

药物批准

按机构分类的批准

EMA

European Medicines Agency

2

药物批准

SFDA

Saudi Food and Drug Authority

2

药物批准

近期批准

资讯

NCFB Pipeline Shows Promise with Over 15 Companies Developing New Therapies

• The non-cystic fibrosis bronchiectasis (NCFB) market is experiencing growth due to rising prevalence and increased awareness, leading to early diagnosis and treatment. • Over 15 companies are actively developing more than 15 NCFB drugs, aiming to improve the treatment landscape for this chronic lung condition. • Key players like Insmed, AstraZeneca, and Verona Pharma are advancing promising therapies such as brensocatib, benralizumab and ensifentrine through clinical trials. • Recent clinical trial milestones, including Phase III results for brensocatib and Phase II enrollment for AP-PA02, signal progress in addressing unmet needs in NCFB treatment.

本页目录

概览
相关临床试验44
药物批准4
资讯1

返回机构列表